Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

This was the stock's second consecutive day of losses.

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

BofA Securities 2025 Health Care Conference May 14, 2025 6:00 PM ETCompany ParticipantsJohn Jacobs - President and CEOJim ...

Shares of Novavax Inc. NVAX shed 2.37% to $6.19 Tuesday, on what proved to be an all-around mixed trading session for the ...

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novavax (NASDAQ:NVAX), a leading player in the biopharmaceutical industry, has seen increasing institutional interest in ...

Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...